Kestra Medical Technologies, Ltd. (KMTS) FY2026 Q1 Statement of Cash Flows

Statement of Cash Flows

2026-05-01 to 2026-07-31

Swipe to see the full flow
Kestra Medical Technologies, Ltd. cash flow reconciliation, May 1, 2026 through Jul 31, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from issuance of long-term debt → financing reconciliation: $75,000,000.00Proceeds from employee stock purchase plan → financing reconciliation: $1,298,000.00Proceeds from stock option exercises → financing reconciliation: $1,140,000.00financing reconciliation → Net cash from financing activities: $22,495,000.00financing reconciliation → Repayment of long-term debt: $46,395,000.00financing reconciliation → Payment of early termination fee on debt repayment: $3,758,000.00financing reconciliation → Payment of debt issuance costs: $3,193,000.00financing reconciliation → Tax withholdings on restricted stock unit vesting: $1,010,000.00financing reconciliation → Payment of equity issuance costs: $415,000.00financing reconciliation → Deemed dividend for payments to third party on behalf of shareholder: $172,000.00Net cash used in investing activities → investing reconciliation: $21,352,000.00investing reconciliation → Purchase of marketable securities: $13,017,000.00investing reconciliation → Purchases of property and equipment: $8,335,000.00Net cash used in operating activities → operating reconciliation: $32,295,000.00Share-based compensation expense → operating reconciliation: $9,517,000.00Loss on extinguishment of debt → operating reconciliation: $6,304,000.00Depreciation and amortization → operating reconciliation: $2,664,000.00Reserve for equipment and supplies → operating reconciliation: $1,464,000.00Amortization of debt discounts and issuance costs → operating reconciliation: $408,000.00Loss on disposal of property and equipment → operating reconciliation: $292,000.00Change in fair value of warrant liabilities → operating reconciliation: $251,000.00Prepaid expenses and other current assets → operating reconciliation: $246,000.00Non-cash lease expense → operating reconciliation: $103,000.00Other long-term assets → operating reconciliation: $2,000.00operating reconciliation → Net loss: $44,087,000.00operating reconciliation → Accrued liabilities: $4,727,000.00operating reconciliation → Accounts payable: $1,879,000.00operating reconciliation → Disposable medical equipment supplies: $908,000.00operating reconciliation → Amortization (accretion) of premiums (discounts) on securities, net: $890,000.00operating reconciliation → (Recovery) provision for uncollectible accounts receivable: $817,000.00operating reconciliation → Operating lease liabilities: $190,000.00operating reconciliation → Accounts receivable: $48,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $100,044,000.00Net cash from financing activities → Cash sources and uses: $22,495,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $68,892,000.00Cash sources and uses → Net cash used in investing activities: $21,352,000.00Cash sources and uses → Net cash used in operating activities: $32,295,000.00Net loss: -$44,087,000.00Net loss−$44.09 MDepreciation and amortization: $2,664,000.00Depreciation & amortization+$2.66 MLoss on disposal of property and equipment: $292,000.00PP&E disposal gain & loss+$292.00 KReserve for equipment and supplies: $1,464,000.00Equipment & supplies reserve+$1.46 M(Recovery) provision for uncollectible accounts receivable: -$817,000.00Receivables provision, net−$817.00 KAmortization (accretion) of premiums (discounts) on securities, net: -$890,000.00Investment discount & premium−$890.00 KLoss on extinguishment of debt: $6,304,000.00Debt extinguishment gain & loss+$6.30 MAmortization of debt discounts and issuance costs: $408,000.00Debt cost amortization+$408.00 KShare-based compensation expense: $9,517,000.00Stock-based compensation+$9.52 MNon-cash lease expense: $103,000.00Non-cash lease expense+$103.00 KChange in fair value of warrant liabilities: $251,000.00Warrant fair value+$251.00 KDisposable medical equipment supplies: -$908,000.00Disposable medical supplies−$908.00 KPrepaid expenses and other current assets: $246,000.00Prepaid & other assets+$246.00 KAccounts receivable: -$48,000.00Accounts receivable−$48.00 KAccounts payable: -$1,879,000.00Accounts payable−$1.88 MAccrued liabilities: -$4,727,000.00Accrued & other liabilities−$4.73 MOperating lease liabilities: -$190,000.00Operating lease liabilities−$190.00 KOther long-term assets: $2,000.00Other noncurrent assets+$2.00 KNet cash used in operating activities: -$32,295,000.00. Cash required to fund net payments.Operating cash−$32.30 Moperating reconciliation: $53,546,000.00Proceeds from issuance of long-term debt: $75,000,000.00Long-term debt issued+$75.00 MPayment of debt issuance costs: -$3,193,000.00Debt issuance costs−$3.19 MRepayment of long-term debt: -$46,395,000.00Long-term debt repaid−$46.40 MPayment of early termination fee on debt repayment: -$3,758,000.00Early termination fee paid−$3.76 MProceeds from stock option exercises: $1,140,000.00Stock option exercises+$1.14 MProceeds from employee stock purchase plan: $1,298,000.00Employee stock plan proceeds+$1.30 MTax withholdings on restricted stock unit vesting: -$1,010,000.00Stock-award tax withholding−$1.01 MDeemed dividend for payments to third party on behalf of shareholder: -$172,000.00Deemed dividend to third party−$172.00 KPayment of equity issuance costs: -$415,000.00Stock issuance costs−$415.00 KNet cash from financing activities: $22,495,000.00Financing cash+$22.50 Mfinancing reconciliation: $77,438,000.00Purchases of property and equipment: -$8,335,000.00PP&E purchases−$8.34 MDeposits for medical rental equipment: $0.00Refund of deposits for medical rental equipment: $0.00Purchase of marketable securities: -$13,017,000.00Marketable securities purchases−$13.02 MNet cash used in investing activities: -$21,352,000.00. Cash required to fund net payments.Investing cash−$21.35 Minvesting reconciliation: $21,352,000.00Cash sources and uses: $122,539,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $100,044,000.00Beginning cash$100.04 MEnding cash: Cash, cash equivalents, and restricted cash: $68,892,000.00Ending cash$68.89 MCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$44.09M + net operating adjustments $11.79M = operating cash −$32.30MFree cash flow−$40.63 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$31.15 MEnding cash − beginning cash
Chart details

Kestra Medical Technologies, Ltd. cash flow reconciliation, May 1, 2026 through Jul 31, 2026

Cash flows for May 1, 2026 through Jul 31, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Apr 30, 2026. Ending cash: Jul 31, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Apr 30, 2026
100,044,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 32,295,000 US dollars. Net cash used.
Net loss
negative 44,087,000 US dollars
Depreciation and amortization
2,664,000 US dollars
Loss on disposal of property and equipment
292,000 US dollars
Reserve for equipment and supplies
1,464,000 US dollars
(Recovery) provision for uncollectible accounts receivable
negative 817,000 US dollars
Amortization (accretion) of premiums (discounts) on securities, net
negative 890,000 US dollars
Loss on extinguishment of debt
6,304,000 US dollars
Amortization of debt discounts and issuance costs
408,000 US dollars
Share-based compensation expense
9,517,000 US dollars
Non-cash lease expense
103,000 US dollars
Change in fair value of warrant liabilities
251,000 US dollars
Disposable medical equipment supplies
negative 908,000 US dollars
Prepaid expenses and other current assets
246,000 US dollars
Accounts receivable
negative 48,000 US dollars
Accounts payable
negative 1,879,000 US dollars
Accrued liabilities
negative 4,727,000 US dollars
Operating lease liabilities
negative 190,000 US dollars
Other long-term assets
2,000 US dollars
Investing activities
negative 21,352,000 US dollars. Net cash used.
Purchases of property and equipment
negative 8,335,000 US dollars
Deposits for medical rental equipment
0 US dollars
Refund of deposits for medical rental equipment
0 US dollars
Purchase of marketable securities
negative 13,017,000 US dollars
Financing activities
22,495,000 US dollars. Net cash provided.
Proceeds from issuance of long-term debt
75,000,000 US dollars
Payment of debt issuance costs
negative 3,193,000 US dollars
Repayment of long-term debt
negative 46,395,000 US dollars
Payment of early termination fee on debt repayment
negative 3,758,000 US dollars
Proceeds from stock option exercises
1,140,000 US dollars
Proceeds from employee stock purchase plan
1,298,000 US dollars
Tax withholdings on restricted stock unit vesting
negative 1,010,000 US dollars
Deemed dividend for payments to third party on behalf of shareholder
negative 172,000 US dollars
Payment of equity issuance costs
negative 415,000 US dollars
Operating adjustment reconciliation
53,546,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
77,438,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
21,352,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jul 31, 2026
68,892,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
122,539,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 31,152,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 32,295,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
8,335,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 40,630,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$44.09M + net operating adjustments $11.79M = operating cash −$32.30M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 32,295,000 US dollars minus 8,335,000 US dollars equals negative 40,630,000 US dollars.
Kestra Medical Technologies, Ltd. (KMTS) FY2026 Q1 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!